UNITED STATES OF AMERICA —Biotechnology firm ADARx Pharmaceuticals completed a USD 446.25 million initial public offering on the Nasdaq Global Select Market, issuing 26.25 million new shares priced at USD 17 per share. Swiss healthcare investment firm HBM Healthcare Investments participated in the offering with a USD 15.3 million capital infusion. This follow-on investment expands HBM’s total exposure in the company to USD 19.3 million, following its initial USD 4 million commitment during a USD 200 million Series C funding round in August 2023. Following the public listing, HBM maintains an approximate 1.2 percent stake in the biotechnology entity, valued at USD 25.4 million based on first-day closing prices.
ADARx Pharmaceuticals is a clinical-stage biotechnology company focused on developing targeted RNA therapeutics, with a core pipeline focused on novel siRNA therapies for rare, complement-mediated, and vascular conditions. HBM Healthcare Investments is a Swiss-listed healthcare investment entity that manages an international portfolio of late-stage biopharmaceutical, medical device, and diagnostic firms across global markets.
The successful listing highlights sustained investor enthusiasm for clinical-stage genetic medicine developers with advanced clinical programs. ADARx is deploying capital toward its primary pipeline asset, onvuzosiran, which is currently undergoing Phase 3 clinical evaluation for hereditary angioedema. Additional proceeds will support clinical and preclinical progress across programs targeting complement system pathologies and hematologic conditions.
For the biopharmaceutical market, the initial public offering underscores institutional liquidity for RNA-focused biotech issuers operating near commercialization. Institutional backers like HBM demonstrate a growing strategic pattern of providing follow-on capital during public market transitions to minimize share dilution and maintain ownership scale. Access to substantial public funding provides ADARx the necessary runway to navigate late-stage clinical trials, regulatory filings, and potential commercial scaling.
